1. Abbruzzese, J. L., M. C. Abbruzzese, K. R. Hess, M. N. Raber, R. Lenzi and P. Frost (1994). "Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients." J Clin Oncol 12(6): 1272-1280.
  2. Ackroyd, S. A., L. Goetsch, J. Brown, K. Houck, C. Wang and E. Hernandez (2019). "Pancreaticobiliary metastasis presenting as primary mucinous ovarian neoplasm: A systematic literature review." Gynecol Oncol Rep 28: 109-115.
  3. Ayoub, J. P., K. R. Hess, M. C. Abbruzzese, R. Lenzi, M. N. Raber and J. L. Abbruzzese (1998). "Unknown primary tumors metastatic to liver." J Clin Oncol 16(6): 2105-2112.
  4. Bahrami, A., L. D. Truong and J. Y. Ro (2008). "Undifferentiated tumor: true identity by immunohistochemistry." Arch Pathol Lab Med 132(3): 326-348.
  5. Bereder, J. M., J. M. Classe, M. Ducreux, D. Elias, G. Ferron, F. Gilly, O. Glehen, G. Lorimier, P. Morice, S. Msika, M. Pocard and F. Quenet (2007). "[Expert agreement on the minimal descriptive surgical report for peritoneal cancer]." J Chir (Paris) 144(5): 463.
  6. Blaszyk, H., A. Hartmann and J. Bjornsson (2003). "Cancer of unknown primary: clinicopathologic correlations." APMIS 111(12): 1089-1094.
  7. Bourgioti, C., M. Konidari and L. A. Moulopoulos (2023). "Manifestations of Ovarian Cancer in Relation to Other Pelvic Diseases by MRI." Cancers (Basel) 15(7).
  8. Bozkurt, M. F., I. Virgolini, S. Balogova, M. Beheshti, D. Rubello, C. Decristoforo, V. Ambrosini, A. Kjaer, R. Delgado-Bolton, J. Kunikowska, W. J. G. Oyen, A. Chiti, F. Giammarile, A. Sundin and S. Fanti (2017). "Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA." Eur J Nucl Med Mol Imaging 44(9): 1588-1601.
  9. Choi, J., J. H. Nahm and S. K. Kim (2017). "Prognostic clinicopathologic factors in carcinoma of unknown primary origin: a study of 106 consecutive cases." Oncotarget 8(37): 62630-62640.
  10. Choi, W. T., R. Ramachandran and S. Kakar (2017). "Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens." Hum Pathol 63: 1-13.
  11. Conner, J. R. and J. L. Hornick (2015). "Metastatic carcinoma of unknown primary: diagnostic approach using immunohistochemistry." Adv Anat Pathol 22(3): 149-167.
  12. Culine, S., A. Kramar, M. Saghatchian, R. Bugat, T. Lesimple, A. Lortholary, Y. Merrouche, A. Laplanche, K. Fizazi and P. French Study Group on Carcinomas of Unknown (2002). "Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site." J Clin Oncol 20(24): 4679-4683.
  13. Culine, S., A. Lortholary, J. J. Voigt, R. Bugat, C. Theodore, F. Priou, M. C. Kaminsky, T. Lesimple, X. Pivot, B. Coudert, J. Y. Douillard, Y. Merrouche, J. Allouache, A. Goupil, S. Negrier, J. Viala, P. Petrow, J. Bouzy, A. Laplanche, K. Fizazi and P. Trial for the French Study Group on Carcinomas of Unknown (2003). "Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)." J Clin Oncol 21(18): 3479-3482.
  14. de Mestier, L., C. Lepage, E. Baudin, R. Coriat, F. Courbon, A. Couvelard, C. Do Cao, E. Frampas, S. Gaujoux, R. Gincul, P. Goudet, C. Lombard-Bohas, G. Poncet, D. Smith, P. Ruszniewski, T. Lecomte, O. Bouche, T. Walter, G. Cadiot and D. Thesaurus National de Cancerologie (2020). "Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)." Dig Liver Dis 52(5): 473-492.
  15. Delhorme, J. B., L. Villeneuve, O. Bouche, G. Averous, A. Dohan, J. M. Gornet, B. You, F. Bibeau, P. Dartigues, C. Eveno, J. Fontaine, V. Kepenekian, M. Pocard, P. Rousset, F. Quenet, P. Mariani, O. Glehen and D. Goere (2022). "Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)." Dig Liver Dis 54(1): 30-39.
  16. Ding, Y., J. Jiang, J. Xu, Y. Chen, Y. Zheng, W. Jiang, C. Mao, H. Jiang, X. Bao, Y. Shen, X. Li, L. Teng and N. Xu (2022). "Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis." ESMO Open 7(2): 100407.
  17. Dowell, J. E., A. M. Garrett, Y. Shyr, D. H. Johnson and K. R. Hande (2001). "A randomized Phase II trial in patients with carcinoma of an unknown primary site." Cancer 91(3): 592-597.
  18. Dragomir, A., M. de Wit, C. Johansson, M. Uhlen and F. Ponten (2014). "The role of SATB2 as a diagnostic marker for tumors of colorectal origin: Results of a pathology-based clinical prospective study." Am J Clin Pathol 141(5): 630-638.
  19. European Association for the Study of the, L. (2016). "EASL Clinical Practice Guidelines on the management of benign liver tumours." J Hepatol 65(2): 386-398.
  20. European Association for the Study of the, L. (2018). "EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma." J Hepatol 69(1): 182-236.
  21. Fizazi, K. (2006). "Treatment of patients with specific subsets of carcinoma of an unknown primary site." Ann Oncol 17 Suppl 10: x177-180.
  22. Flanagan, M., J. Solon, K. H. Chang, S. Deady, B. Moran, R. Cahill, C. Shields and J. Mulsow (2018). "Peritoneal metastases from extra-abdominal cancer - A population-based study." Eur J Surg Oncol 44(11): 1811-1817.
  23. Gatalica, Z., J. Xiu, J. Swensen and S. Vranic (2018). "Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy." Eur J Cancer 94: 179-186.
  24. Golfinopoulos, V., G. Pentheroudakis, G. Salanti, A. D. Nearchou, J. P. Ioannidis and N. Pavlidis (2009). "Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis." Cancer Treat Rev 35(7): 570-573.
  25. Gonzalez-Martin, A., B. Pothuri, I. Vergote, R. DePont Christensen, W. Graybill, M. R. Mirza, C. McCormick, D. Lorusso, P. Hoskins, G. Freyer, K. Baumann, K. Jardon, A. Redondo, R. G. Moore, C. Vulsteke, R. E. O'Cearbhaill, B. Lund, F. Backes, P. Barretina-Ginesta, A. F. Haggerty, M. J. Rubio-Perez, M. S. Shahin, G. Mangili, W. H. Bradley, I. Bruchim, K. Sun, I. A. Malinowska, Y. Li, D. Gupta, B. J. Monk and P. E.-O. G.-. Investigators (2019). "Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer." N Engl J Med 381(25): 2391-2402.
  26. Goodman, M. T. and Y. B. Shvetsov (2009). "Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004." Cancer Epidemiol Biomarkers Prev 18(1): 132-139.
  27. Goyal, L., F. Meric-Bernstam, A. Hollebecque, J. W. Valle, C. Morizane, T. B. Karasic, T. A. Abrams, J. Furuse, R. K. Kelley, P. A. Cassier, H. J. Klumpen, H. M. Chang, L. T. Chen, J. Tabernero, D. Y. Oh, A. Mahipal, M. Moehler, E. P. Mitchell, Y. Komatsu, K. Masuda, D. Ahn, R. S. Epstein, A. B. Halim, Y. Fu, T. Salimi, V. Wacheck, Y. He, M. Liu, K. A. Benhadji, J. A. Bridgewater and F.-C. S. Investigators (2023). "Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma." N Engl J Med 388(3): 228-239.
  28. Greco, F. A., J. B. Erland, L. H. Morrissey, H. A. Burris, 3rd, R. C. Hermann, R. Steis, D. Thompson, J. Gray and J. D. Hainsworth (2000). "Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin." Ann Oncol 11(2): 211-215.
  29. Hainsworth, J. D. and K. Fizazi (2009). "Treatment for patients with unknown primary cancer and favorable prognostic factors." Semin Oncol 36(1): 44-51.
  30. Hainsworth, J. D., D. R. Spigel, H. A. Burris, 3rd, D. Shipley, C. Farley, I. M. Macias-Perez, J. Barton and F. A. Greco (2010). "Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium." Cancer 116(10): 2448-2454.
  31. Hainsworth, J. D., D. R. Spigel, C. Farley, D. S. Thompson, D. L. Shipley, F. A. Greco and N. Minnie Pearl Cancer Research (2007). "Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network." J Clin Oncol 25(13): 1747-1752.
  32. Holtan, S. G., P. D. Steen, N. R. Foster, C. Erlichman, F. Medeiros, M. M. Ames, S. L. Safgren, D. L. Graham, R. J. Behrens and M. P. Goetz (2012). "Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial." PLoS One 7(7): e39285.
  33. Jacquin, N., M. Kamal, C. Le Tourneau and S. Watson (2022). "Cancer of unknown primary: a national multidisciplinary consultation board for diagnostic and therapeutic orientation." Innovations & Thérapeutiques en Oncologie 8(6): 295-298.
  34. Kato, M. K., D. Shida, Y. Yoneoka, H. Yoshida, N. Miyasaka, Y. Kanemitsu and T. Kato (2020). "Novel classification of ovarian metastases originating from colorectal cancer by radiological imaging and macroscopic appearance." Int J Clin Oncol 25(9): 1663-1671.
  35. Kato, S., A. Alsafar, V. Walavalkar, J. Hainsworth and R. Kurzrock (2021). "Cancer of unknown primary in the molecular era." Trends in cancer 7(5): 465-477.
  36. Kato, S., N. Krishnamurthy, K. C. Banks, P. De, K. Williams, C. Williams, B. Leyland-Jones, S. M. Lippman, R. B. Lanman and R.
  37. Kurzrock (2017). "Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary." Cancer Res 77(16): 4238-4246.
  38. Katoh, M., Y. Loriot, G. Brandi, S. Tavolari, Z. A. Wainberg and M. Katoh (2024). "FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions." Nat Rev Clin Oncol 21(4): 312-329.
  39. Kim, Y. Y., S. K. Yeom, H. Shin, S. H. Choi, H. Rhee, J. H. Park, E. S. Cho, S. Park, S. S. Lee and M. S. Park (2021). "Clinical Staging of Mass-Forming Intrahepatic Cholangiocarcinoma: Computed Tomography Versus Magnetic Resonance Imaging." Hepatol Commun 5(12): 2009-2018.
  40. Kovac, J. D., A. Jankovic, A. Dikic-Rom, N. Grubor, A. Antic and V. Dugalic (2022). "Imaging Spectrum of Intrahepatic Mass-Forming Cholangiocarcinoma and Its Mimickers: How to Differentiate Them Using MRI." Curr Oncol 29(2): 698-723.
  41. Kramer, A., T. Bochtler, C. Pauli, G. Baciarello, S. Delorme, K. Hemminki, L. Mileshkin, H. Moch, K. Oien, T. Olivier, A. Patrikidou, H. Wasan, G. Zarkavelis, G. Pentheroudakis, K. Fizazi and E. G. C. E. a. clinicalguidelines@esmo.org (2023). "Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up." Ann Oncol 34(3): 228-246.
  42. Kramer, A., T. Bochtler, C. Pauli, K. K. Shiu, N. Cook, J. J. de Menezes, R. A. Pazo-Cid, F. Losa, D. G. Robbrecht, J. Tomasek, C. Arslan, M. Ozguroglu, M. Stahl, F. Bigot, S. Y. Kim, Y. Naito, A. Italiano, N. Chalabi, G. Duran-Pacheco, C. Michaud, J. Scarato, M. Thomas, J. S. Ross, H. Moch and L. Mileshkin (2024). "Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study." Lancet 404(10452): 527-539.
  43. Kurokawa, R., Y. Nakai, W. Gonoi, H. Mori, T. Tsuruga, N. Makise, T. Ushiku and O. Abe (2020). "Differentiation between ovarian metastasis from colorectal carcinoma and primary ovarian carcinoma: Evaluation of tumour markers and "mille-feuille sign" on computed tomography/magnetic resonance imaging." Eur J Radiol 124: 108823.
  44. Le Chevalier, T., E. Cvitkovic, P. Caille, J. Harvey, G. Contesso, M. Spielmann and J. Rouesse (1988). "Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients." Arch Intern Med 148(9): 2035-2039.
  45. Lin, F., J. Shi, S. Zhu, Z. Chen, A. Li, T. Chen, H. L. Wang and H. Liu (2014). "Cadherin-17 and SATB2 are sensitive and specific immunomarkers for medullary carcinoma of the large intestine." Arch Pathol Lab Med 138(8): 1015-1026.
  46. Liu, X., X. Zhang, S. Jiang, M. Mo, Q. Wang, Y. Wang, L. Zhou, S. Hu, H. Yang, Y. Hou, Y. Chen, X. Lu, Y. Wang, X. Zhou, W. Li, C. Chang, X. Yang, K. Chen, J. Cao, Q. Xu, Y. Sun, J. Luo, Z. Luo and X. Hu (2024). "Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial." Lancet Oncol 25(8): 1092-1102.
  47. Lobo, J., B. Machado, R. Vieira and C. Bartosch (2017). "The challenge of diagnosing a malignancy metastatic to the ovary: clinicopathological characteristics vary and morphology can be different from that of the corresponding primary tumor." Virchows Arch 470(1): 69-80.
  48. Losa, F., I. Fernández, O. Etxaniz, A. Giménez, P. Gomila, L. Iglesias, F. Longo, E. Nogales, A. Sánchez and G. Soler (2022). "SEOM—GECOD clinical guideline for unknown primary cancer (2021)." Clinical and Translational Oncology 24(4): 681-692.
  49. Lugli, A., A. Tzankov, I. Zlobec and L. M. Terracciano (2008). "Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status." Mod Pathol 21(11): 1403-1412.
  50. Ma, H., Y. Kan and J. G. Yang (2021). "Clinical value of (68)Ga-DOTA-SSTR PET/CT in the diagnosis and detection of neuroendocrine tumors of unknown primary origin: a systematic review and meta-analysis." Acta Radiol 62(9): 1217-1228.
  51. Massard, C., Y. Loriot and K. Fizazi (2011). "Carcinomas of an unknown primary origin--diagnosis and treatment." Nat Rev Clin Oncol 8(12): 701-710.
  52. Massard, C., Y. Loriot and K. Fizazi (2011). "Carcinomas of an unknown primary origin—diagnosis and treatment." Nature reviews Clinical oncology 8(12): 701-710.
  53. Mohrmann, L., M. Werner, M. Oles, A. Mock, S. Uhrig, A. Jahn, S. Kreutzfeldt, M. Frohlich, B. Hutter, N. Paramasivam, D. Richter, K. Beck, U. Winter, K. Pfutze, C. E. Heilig, V. Teleanu, D. B. Lipka, M. Zapatka, D. Hanf, C. List, M. Allgauer, R. Penzel, G. Ruter, I. Jelas, R. Hamacher, J. Falkenhorst, S. Wagner, C. H. Brandts, M. Boerries, A. L. Illert, K. H. Metzeler, C. B. Westphalen, A. Desuki, T. Kindler, G. Folprecht, W. Weichert, B. Brors, A. Stenzinger, E. Schrock, D. Hubschmann, P. Horak, C. Heining, S. Frohling and H. Glimm (2022). "Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity." Nat Commun 13(1): 4485.
  54. Molinie, V. (2008). "[The role of the pathologist in the diagnosis of metastases from urological malignancies]." Prog Urol 18 Suppl 7: S178-195.
  55. Moschetta, M., A. George, S. B. Kaye and S. Banerjee (2016). "BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer." Ann Oncol 27(8): 1449-1455.
  56. Neri, E., M. A. Bali, A. Ba-Ssalamah, P. Boraschi, G. Brancatelli, F. C. Alves, L. Grazioli, T. Helmberger, J. M. Lee, R. Manfredi, L. Marti-Bonmati, C. Matos, E. M. Merkle, B. Op De Beeck, W. Schima, S. Skehan, V. Vilgrain, C. Zech and C. Bartolozzi (2016). "ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents." Eur Radiol 26(4): 921-931.
  57. Neumann, K. H. and J. S. Nystrom (1982). "Metastatic cancer of unknown origin: nonsquamous cell type." Semin Oncol 9(4): 427-434.
  58. Neuzillet, C., S. Gaujoux, N. Williet, J. B. Bachet, L. Bauguion, L. Colson Durand, T. Conroy, L. Dahan, M. Gilabert, F. Huguet, L. Marthey, J. Meilleroux, L. de Mestier, B. Napoleon, F. Portales, A. Sa Cunha, L. Schwarz, J. Taieb, B. Chibaudel, O. Bouche, P. Hammel, D. Thesaurus National de Cancerologie, (2018). "Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC)." Dig Liver Dis 50(12): 1257-1271.
  59. Olsen, J., S. Eiholm, L. T. Kirkeby, M. L. Espersen, P. Jess, I. Gogenur, J. Olsen and J. T. Troelsen (2016). "CDX2 downregulation is associated with poor differentiation and MMR deficiency in colon cancer." Exp Mol Pathol 100(1): 59-66.
  60. Ozcan, A., S. S. Shen, C. Hamilton, K. Anjana, D. Coffey, B. Krishnan and L. D. Truong (2011). "PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study." Mod Pathol 24(6): 751-764.
  61. Pavlidis, N. and G. Pentheroudakis (2012). "Cancer of unknown primary site." Lancet 379(9824): 1428-1435.
  62. Pavlidis, N., D. Petrakis, V. Golfinopoulos and G. Pentheroudakis (2012). "Long-term survivors among patients with cancer of unknown primary." Crit Rev Oncol Hematol 84(1): 85-92.
  63. Pouyiourou, M., T. Wohlfromm, B. Kraft, T. Hielscher, D. Stichel, A. von Deimling, S. Delorme, V. Endris, O. Neumann, A. Stenzinger, A. Kramer and T. Bochtler (2021). "Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary." Eur J Cancer 157: 179-189.
  64. Qi, P., Y. Sun, X. Liu, S. Wu, Y. Wo, Q. Xu, Q. Wang, X. Hu and X. Zhou (2023). "Clinicopathological, molecular and prognostic characteristics of cancer of unknown primary in China: An analysis of 1420 cases." Cancer Med 12(2): 1177-1188.
  65. Queisser, A., S. A. Hagedorn, M. Braun, W. Vogel, S. Duensing and S. Perner (2015). "Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer." Mod Pathol 28(1): 138-145.
  66. Rassy, E. and F. Andre (2024). "New clinical trials in CUP and a novel paradigm in cancer classification." Nat Rev Clin Oncol.
  67. Rassy, E., T. Assi, S. Boussios, J. Kattan, J. Smith-Gagen and N. Pavlidis (2020). "Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered." Ann Transl Med 8(24): 1709.
  68. Rassy, E., T. Assi and N. Pavlidis (2020). "Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?" Br J Cancer 122(8): 1124-1132.
  69. Rassy, E. and N. Pavlidis (2019). "The currently declining incidence of cancer of unknown primary." Cancer Epidemiol 61: 139-141.
  70. Ross, J. S., E. S. Sokol, H. Moch, L. Mileshkin, G. Baciarello, F. Losa, A. Beringer, M. Thomas, J. A. Elvin and N. Ngo (2021). "Comprehensive genomic profiling of carcinoma of unknown primary origin: retrospective molecular classification considering the CUPISCO study design." The oncologist 26(3): e394-e402.
  71. Ross, J. S., K. Wang, L. Gay, G. A. Otto, E. White, K. Iwanik, G. Palmer, R. Yelensky, D. M. Lipson, J. Chmielecki, R. L. Erlich, A. N.
  72. Rankin, S. M. Ali, J. A. Elvin, D. Morosini, V. A. Miller and P. J. Stephens (2015). "Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies." JAMA Oncol 1(1): 40-49.
  73. Roy, S., M. A. Smith, K. M. Cieply, M. B. Acquafondata and A. V. Parwani (2012). "Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge." Diagn Pathol 7: 151.
  74. Salaun, P. Y., R. Abgral, O. Malard, S. Querellou-Lefranc, G. Quere, M. Wartski, R. Coriat, E. Hindie, D. Taieb, A. Tabarin, A. Girard, J. F. Grellier, I. Brenot-Rossi, D. Groheux, C. Rousseau, D. Deandreis, J. L. Alberini, C. Bodet-Milin, E. Itti, O. Casasnovas, F. Kraeber-Bodere, P. Moreau, A. Philip, C. Balleyguier, A. Lucian and F. Cachin (2019). "[Update of the recommendations of good clinical practice for the use of PET in oncology]." Bull Cancer 106(3): 262-274.
  75. Sheridan, T., M. Herawi, J. I. Epstein and P. B. Illei (2007). "The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate." Am J Surg Pathol 31(9): 1351-1355.
  76. Skinnider, B. F. and M. B. Amin (2005). "An immunohistochemical approach to the differential diagnosis of renal tumors." Semin Diagn Pathol 22(1): 51-68.
  77. Skirnisdottir, I., H. Garmo and L. Holmberg (2007). "Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990-2003: occurrence, origin and survival compared to ovarian cancer." Gynecol Oncol 105(1): 166-171.
  78. Spencer, J. A., M. J. Weston, S. A. Saidi, N. Wilkinson and G. D. Hall (2010). "Clinical utility of image-guided peritoneal and omental biopsy." Nat Rev Clin Oncol 7(11): 623-631.
  79. Spigel, D. R., J. D. Hainsworth and F. A. Greco (2009). "Neuroendocrine carcinoma of unknown primary site." Semin Oncol 36(1): 52-59.
  80. Sugarbaker, P. H. (2020). "Peritoneal carcinomatosis of unknown primary site, a study of 25 patients over 30 years." Eur J Surg Oncol 46(10 Pt A): 1908-1911.
  81. Tanizaki, J., K. Yonemori, K. Akiyoshi, H. Minami, H. Ueda, Y. Takiguchi, Y. Miura, Y. Segawa, S. Takahashi, Y. Iwamoto, Y. Kidera, K. Fukuoka, A. Ito, Y. Chiba, K. Sakai, K. Nishio, K. Nakagawa and H. Hayashi (2022). "Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary." Ann Oncol 33(2): 216-226.
  82. Taylor, E. C., L. Irshaid and M. Mathur (2021). "Multimodality Imaging Approach to Ovarian Neoplasms with Pathologic Correlation." Radiographics 41(1): 289-315.
  83. Thelissen, A. A. B., I. M. Jurgenliemk-Schulz, F. van der Leij, M. Peters, C. G. Gerestein, R. P. Zweemer and P. S. N. van Rossum (2022). "Upstaging by para-aortic lymph node dissection in patients with locally advanced cervical cancer: A systematic review and meta-analysis." Gynecol Oncol 164(3): 667-674.
  84. Thomassen, I., R. H. Verhoeven, Y. R. van Gestel, A. J. van de Wouw, V. E. Lemmens and I. H. de Hingh (2014). "Population-based incidence, treatment and survival of patients with peritoneal metastases of unknown origin." Eur J Cancer 50(1): 50-56.
  85. Thomassin-Naggara, I., M. Belghitti, A. Milon, C. Abdel Wahab, E. Sadowski, A. G. Rockall and E. s. group (2021). "O-RADS MRI score: analysis of misclassified cases in a prospective multicentric European cohort." Eur Radiol 31(12): 9588-9599.
    Trullas, A., J. Delgado, A. Genazzani, J. Mueller-Berghaus, C. Migali, S. Muller-Egert, H. Zander, H. Enzmann and F. Pignatti (2021). "The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer." ESMO Open 6(3): 100145.
  86. Vandecaveye, V., P. Rousset, S. Nougaret, A. Stepanyan, M. Otero-Garcia, O. Nikolic, M. Hameed, K. Goffin, I. H. J. de Hingh, M. J. Lahaye, G. European Society of, R. Abdominal, R. European Society of Urogenital, I. Peritoneal Surface Oncology Group and M. European Association of Nuclear (2024). "Imaging of peritoneal metastases of ovarian and colorectal cancer: joint recommendations of ESGAR, ESUR, PSOGI, and EANM." Eur Radiol.
  87. Varadhachary, G. R. and M. N. Raber (2014). "Cancer of unknown primary site." N Engl J Med 371(8): 757-765.
    Varadhachary, G. R., M. N. Raber, A. Matamoros and J. L. Abbruzzese (2008). "Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions." Lancet Oncol 9(6): 596-599.
  88. Varghese, A. M., A. Arora, M. Capanu, N. Camacho, H. H. Won, A. Zehir, J. Gao, D. Chakravarty, N. Schultz, D. S. Klimstra, M. Ladanyi, D. M. Hyman, D. B. Solit, M. F. Berger and L. B. Saltz (2017). "Clinical and molecular characterization of patients with cancer of unknown primary in the modern era." Ann Oncol 28(12): 3015-3021.
  89. Vibert, J., G. Pierron, C. Benoist, N. Gruel, D. Guillemot, A. Vincent-Salomon, C. Le Tourneau, A. Livartowski, O. Mariani, S. Baulande, F. C. Bidard, O. Delattre, J. J. Waterfall and S. Watson (2021). "Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics)." J Mol Diagn 23(10): 1380-1392.
  90. Villeneuve, L., G. Passot, O. Glehen, S. Isaac, F. Bibeau, P. Rousset, F. N. Gilly and R. Network (2017). "The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry." Orphanet J Rare Dis 12(1): 37.
  91. Willemse, J. R. J., D. M. J. Lambregts, S. Balduzzi, W. Schats, P. Snaebjornsson, S. Marchetti, M. A. Vollebergh, L. W. van Golen, Z. Cheung, W. V. Vogel, Z. Bodalal, S. Rostami, O. Gerke, T. Sivakumaran, R. G. H. Beets-Tan and M. J. Lahaye (2024). "Identifying the primary tumour in patients with cancer of unknown primary (CUP) using [(18)F]FDG PET/CT: a systematic review and individual patient data meta-analysis." Eur J Nucl Med Mol Imaging 52(1): 225-236.
  92. Xu, Y., J. Yang, Z. Zhang and G. Zhang (2015). "MRI for discriminating metastatic ovarian tumors from primary epithelial ovarian cancers." J Ovarian Res 8: 61.
  93. Yu, H., J. Wang, B. Wu, J. Li and R. Chen (2023). "Prognostic significance and risk factors for pelvic and para-aortic lymph node metastasis in type I and type II ovarian cancer: a large population-based database analysis." J Ovarian Res 16(1): 28.
  94. Zech, C. J., A. Ba-Ssalamah, T. Berg, H. Chandarana, G. Y. Chau, L. Grazioli, M. J. Kim, J. M. Lee, E. M. Merkle, T. Murakami, J. Ricke, B. S. C, B. Song, B. Taouli, K. Yoshimitsu and D. M. Koh (2020). "Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging." Eur Radiol 30(1): 370-382.
  95. Zhang, J. J., D. Y. Cao, J. X. Yang and K. Shen (2020). "Ovarian metastasis from nongynecologic primary sites: a retrospective analysis of 177 cases and 13-year experience." J Ovarian Res 13(1): 128.
  96. Zhao, Y., Z. Pan, S. Namburi, A. Pattison, A. Posner, S. Balachander, C. A. Paisie, H. V. Reddi, J. Rueter, A. J. Gill, S. Fox, K. P. S. Raghav, W. F. Flynn, R. W. Tothill, S. Li, R. K. M. Karuturi and J. George (2020). "CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence." EBioMedicine 61: 103030.
  97. Zhou, X. X., H. H. Pan, A. Usman, F. Ji, X. Jin, W. X. Zhong and H. T. Chen (2015). "Endoscopic ultrasound-guided deep and large biopsy for diagnosis of gastric infiltrating tumors with negative malignant endoscopy biopsies." World J Gastroenterol 21(12): 3607-3613.